If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
90.00    0.00 (0.00%)
Bid:
85.00
Ask:
95.00
Spread: 10.00 (11.765%)
Market Cap: £5.92m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
1st May 20077:01 amRNSBlocklisting Interim Review
30th Apr 20074:53 pmRNSTotal Voting Rights
30th Apr 20079:15 amRNSAnnual Report and Accounts
19th Apr 20074:46 pmRNSDirector/PDMR Shareholding
29th Mar 20072:56 pmRNSFinal Results
22nd Mar 20072:42 pmRNSHolding(s) in Company
20th Mar 20079:31 amRNSNotice of Results
21st Dec 20062:26 pmRNSTotal Voting Rights
18th Dec 20062:52 pmRNSIssue of Equity
8th Dec 20067:01 amRNSIntelligent Data Acquisition
30th Nov 20066:16 pmRNSAcqu. and Trading Update
1st Nov 200610:36 amRNSBlocklisting Interim Review
12th Sep 20064:01 pmRNSDirector/PDMR Shareholding
22nd Aug 20067:00 amRNSFirst Day of Dealings
21st Aug 200611:42 amRNSEGM Statement
14th Aug 20065:50 pmRNSResult of AGM
14th Aug 20067:00 amRNSAGM Statement
4th Aug 20063:35 pmRNSSwansea Property
31st Jul 20061:35 pmRNSHolding(s) in Company
31st Jul 200611:39 amRNSHolding(s) in Company
27th Jul 20062:57 pmRNSSch 1 - Cohen(A.) & Co PLC
27th Jul 20067:01 amRNSAcquisition of Crimson Tide
30th Jun 20067:01 amRNSFinal Results
8th Mar 20062:39 pmRNSChange of registered address
2nd Mar 20067:00 amRNSChange of Adviser
8th Feb 20062:58 pmRNSDisposal
30th Sep 200511:41 amRNSInterim Results
30th Jun 20055:25 pmRNSFinal Results
21st Feb 200511:11 amRNSRule 8 - Cohen(A.) & Co PLC
21st Feb 200510:52 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.